A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy.

Registry ID

EUCTR2007-005639-26

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Oxford BioMedica

Start date

2008-03-14

Completion date

2009-10-31

Last update

2026-08-16

Conditions

• Metastatic Colorectal Adenocarcinoma. ----------------------------------------------- Adenocarcinoma Colorectal Metastásico.
• Metastatic Colorectal Adenocarcinoma

Summary

- To compare overall survival (OS) with TroVax vs. Placebo in patients with metastatic colorectal cancer receiving chemo-based therapy in first line treatment.

Locations

• , , Germany
• , , Spain
• , , UK

Related clinical trials

• Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
• Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
• Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

View on source registry